Review: The fate of cell grafts for the treatment of Huntington's disease: The post-mortem evidence

Neuropathology and Applied Neurobiology

Volumn 40, Issue 1, 2014, Pages 71-90

  Cisbani, G ^a   Cicchetti, F ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cell transplantation; Excitotoxicity; Inflammation; Mutant huntingtin; Neurotrophic factors; Vasculature

Indexed keywords

AUTOPSY; AUTOSOMAL DOMINANT DISORDER; BRAIN ATROPHY; CELL FATE; CELL TRANSPLANTATION; GENETIC ENGINEERING; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; EXCITOTOXICITY; INFLAMMATION; NEUROTROPHIC FACTORS; VASCULARIZATION;

MUTANT HUNTINGTIN;

CELL TRANSPLANTATION; EXCITOTOXICITY; INFLAMMATION; MUTANT HUNTINGTIN; NEUROTROPHIC FACTORS; VASCULATURE;

CELL TRANSPLANTATION; HUMANS; HUNTINGTON DISEASE;

EID: 84892498964     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12104     Document Type: Review

References (164)

1. Backlund EO, Granberg PO, Hamberger B, Knutsson E, Mårtensson A, Sedvall G, Seiger A, Olson L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985; 62: 169-173
2. Lindvall O, Backlund EO, Farde L, Sedvall G, Freedman R, Hoffer B, Nobin A, Seiger A, Olson L. Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol 1987; 22: 457-468
3. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, Lindholm T, Björklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden D, Johnels B, Steg G, Freedman R, Hoffer BJ, Seiger A, Bygdeman M, Strömberg I, Olson L. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46: 615-631
4. Lindvall O, Rehncrona S, Gustavii B, Brundin P, Astedt B, Widner H, Lindholm T, Björklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden CD, Johnels B, Steg G, Freedman R, Hoffer BJ, Seiger L, Strömberg I, Bygdeman M, Olson L. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 1988; 2: 1483-1484
5. Lindvall O, Björklund A. Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials. Acta Neurol Scand Suppl 1989; 126: 197-210
6. Giordana MT, Grifoni S, Votta B, Magistrello M, Vercellino M, Pellerino A, Navone R, Valentini C, Calvo A, Chiò A. Neuropathology of olfactory ensheathing cell transplantation into the brain of two amyotrophic lateral sclerosis (ALS) patients. Brain Pathol 2010; 20: 730-737
7. Huang H, Chen L, Xi H, Wang H, Zhang J, Zhang F, Liu Y. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant 2008; 22: 710-718
8. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, Testa L, Stecco A, Tarletti R, Miglioretti M, Fava E, Nasuelli N, Cisari C, Massara M, Vercelli R, Oggioni GD, Carriero A, Cantello R, Monaco F, Fagioli F. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol 2010; 223: 229-237
9. Mazzini L, Mareschi K, Ferrero I, Miglioretti M, Stecco A, Servo S, Carriero A, Monaco F, Fagioli F. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 2012; 14: 56-60
10. Uccelli A, Mancardi G. Stem cell transplantation in multiple sclerosis. Curr Opin Neurol 2010; 23: 218-225
11. Rice CM, Kemp K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 2013; 382: 1204-1213
12. Kondziolka D, Wechsler L, Gebel J, DeCesare S, Elder E, Meltzer CC. Neuronal transplantation for motor stroke: from the laboratory to the clinic. Phys Med Rehabil Clin N Am 2003; 14: S153-160, xi
13. Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis 2005; 20: 101-107
14. Féron F, Perry C, Cochrane J, Licina P, Nowitzke A, Urquhart S, Geraghty T, Mackay-Sim A. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005; 128: 2951-2960
15. Ramón-Cueto A, Santos-Benito FF. Cell therapy to repair injured spinal cords: olfactory ensheathing glia transplantation. Restor Neurol Neurosci 2001; 19: 149-156
16. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998; 149: 97-108
17. Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002; 58: 687-695
18. Bachoud-Lévi A, Bourdet C, Brugières P, Nguyen JP, Grandmougin T, Haddad B, Jény R, Bartolomeo P, Boissé MF, Barba GD, Degos JD, Ergis AM, Lefaucheur JP, Lisovoski F, Pailhous E, Rémy P, Palfi S, Defer GL, Cesaro P, Hantraye P, Peschanski M. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000; 161: 194-202
19. Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB, NEST-UK. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no. 36485475. J Neurol Neurosurg Psychiatry 2002; 73: 678-685
20. Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason S, Polkey CE, Clough C, Brooks DJ, Barker RA, Piccini P. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry 2008; 79: 948-951
21. Gallina P, Paganini M, Lombardini L, Mascalchi M, Porfirio B, Gadda D, Marini M, Pinzani P, Salvianti F, Crescioli C, Bucciantini S, Mechi C, Sarchielli E, Romoli AM, Bertini E, Urbani S, Bartolozzi B, De Cristofaro MT, Piacentini S, Saccardi R, Pupi A, Vannelli GB, Di Lorenzo N. Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol 2010; 222: 30-41
22. Capetian P, Knoth R, Maciaczyk J, Pantazis G, Ditter M, Bokla L, Landwehrmeyer GB, Volk B, Nikkhah G. Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation. Neuroscience 2009; 160: 661-675
23. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EPJ. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577
24. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98
25. Li J-Y, Conforti L. Axonopathy in Huntington's disease. Exp Neurol 2013; 246: 62-71
26. Lee CYD, Cantle JP, Yang XW. Genetic manipulations of mutant huntingtin in mice: new insights into HD pathogenesis. FEBS J 2013; 280: 4382-4394
27. Cardoso F. Huntington disease and other choreas. Neurol Clin 2009; 27: 719-736, vi
28. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000; 97: 6763-6768
29. Cisbani G, Cicchetti F. An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis 2012; 3: e382
30. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-981
31. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008; 23: 1491-1504
32. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574-577
33. Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res 2000; 127: 299-320
34. Schmidt RH, Björklund A, Stenevi U. Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res 1981; 218: 347-356
35. Deckel AW, Moran TH, Coyle JT, Sanberg PR, Robinson RG. Anatomical predictors of behavioral recovery following fetal striatal transplants. Brain Res 1986; 365: 249-258
36. Isacson O, Dunnett SB, Björklund A. Graft-induced behavioral recovery in an animal model of Huntington disease. Proc Natl Acad Sci USA 1986; 83: 2728-2732
37. Isacson O, Brundin P, Kelly PA, Gage FH, Björklund A. Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature 1984; 311: 458-460
38. Sanberg PR, Henault MA, Deckel AW. Locomotor hyperactivity: effects of multiple striatal transplants in an animal model of Huntington's disease. Pharmacol Biochem Behav 1986; 25: 297-300
39. Wictorin K, Isacson O, Fischer W, Nothias F, Peschanski M, Björklund A. Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum - I. Subcortical afferents. Neuroscience 1988; 27: 547-562
40. Wictorin K, Clarke DJ, Bolam JP, Björklund A. Host corticostriatal fibres establish synaptic connections with grafted striatal neurons in the ibotenic acid lesioned striatum. Eur J Neurosci 1989; 1: 189-195
41. Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, Tai YF, Brooks DJ, Pavese N, Watts C, Pickard JD, Rosser AE, Dunnett SB, the NEST-UK collaboration. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 2013; 84: 657-665
42. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci USA 2000; 97: 13877-13882
43. Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, Li XJ, Parker JR, Chu Y, Mufson EJ, Kordower JH, Freeman TB. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci USA 2009; 106: 12483-12488
44. Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, Hauser RA, Barker RA, Cicchetti F. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain 2013; 136: 433-443
45. Keene CD, Chang RC, Leverenz JB, Kopyov O, Perlman S, Hevner RF, Born DE, Bird TD, Montine TJ. A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol 2009; 117: 329-338
46. Keene CD, Sonnen JA, Swanson PD, Kopyov O, Leverenz JB, Bird TD, Born DE, Bird TD, Montine TJ. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007; 68: 2093-2098
47. Ross BD, Hoang TQ, Blüml S, Dubowitz D, Kopyov OV, Jacques DB, Lin A, Seymour K, Tan J. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 1999; 12: 221-236
48. Bachoud-Lévi AC, Rémy P, Nguyen JP, Brugières P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boissé MF, Grandmougin T, Jény R, Bartolomeo P, Dalla Barba G, Degos JD, Lisovoski F, Ergis AM, Pailhous E, Cesaro P, Hantraye P, Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000; 356: 1975-1979
49. Gaura V, Bachoud-Lévi A-C, Ribeiro M-J, Nguyen J-P, Frouin V, Baudic S, Brugières P, Mangin J-F, Boissé M-F, Palfi S, Cesaro P, Samson Y, Hantraye P, Peschanski M, Remy P. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 2004; 127: 65-72
50. Bachoud-Lévi A-C, Gaura V, Brugières P, Lefaucheur J-P, Boissé M-F, Maison P, Baudic S, Ribeiro M-J, Bourdet C, Remy P, Cesaro P, Hantraye P, Peschanski M. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006; 5: 303-309
51. Krystkowiak P, Gaura V, Labalette M, Rialland A, Remy P, Peschanski M, Bachoud-Lévi A-C. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS ONE 2007; 2: e166
52. Gallina P, Paganini M, Lombardini L, Saccardi R, Marini M, De Cristofaro MT, Pinzani P, Salvianti F, Crescioli C, Di Rita A, Bucciantini S, Mechi C, Sarchielli E, Moretti M, Piacentini S, Gritti G, Bosi A, Sorbi S, Orlandini G, Vannelli GB, Di Lorenzo N. Development of human striatal anlagen after transplantation in a patient with Huntington's disease. Exp Neurol 2008; 213: 241-244
53. Beal MF, Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proc Natl Acad Sci USA 2001; 98: 3-4
54. Graybiel AM, Liu FC, Dunnett SB. Intrastriatal grafts derived from fetal striatal primordia. I. Phenotypy and modular organization. J Neurosci 1989; 9: 3250-3271
55. Hantraye P, Riche D, Maziere M, Isacson O. Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci USA 1992; 89: 4187-4191
56. Kendall AL, Rayment FD, Torres EM, Baker HF, Ridley RM, Dunnett SB. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998; 4: 727-729
57. Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE, Brooks DJ. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996; 11: 167-173
58. Levine MS, Cepeda C, André VM. Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease. Neuron 2010; 65: 145-147
59. Cross AJ, Slater P, Reynolds GP. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. Neurosci Lett 1986; 67: 198-202
60. Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 2007; 27: 12908-12915
61. Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011; 198: 252-273
62. André VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010; 16: 163-178
63. Tang T-S, Chen X, Liu J, Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 2007; 27: 7899-7910
64. Scheckenbach KEL, Crespin S, Kwak BR, Chanson M. Connexin channel-dependent signaling pathways in inflammation. J Vasc Res 2011; 48: 91-103
65. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577
66. Vis JC, Nicholson LF, Faull RL, Evans WH, Severs NJ, Green CR. Connexin expression in Huntington's diseased human brain. Cell Biol Int 1998; 22: 837-847
67. Shin J-Y, Fang Z-H, Yu Z-X, Wang C-E, Li S-H, Li X-J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005; 171: 1001-1012
68. Hassel B, Tessler S, Faull RLM, Emson PC. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008; 33: 232-237
69. Jäderstad J, Jäderstad LM, Herlenius E. Dynamic changes in connexin expression following engraftment of neural stem cells to striatal tissue. Exp Cell Res 2011; 317: 70-81
70. Jäderstad J, Jäderstad LM, Li J, Chintawar S, Salto C, Pandolfo M, Ourednik V, Teng YD, Sidman RL, Arenas E, Snyder EY, Herlenius E. Communication via gap junctions underlies early functional and beneficial interactions between grafted neural stem cells and the host. Proc Natl Acad Sci USA 2010; 107: 5184-5189
71. Theis M, Giaume C. Connexin-based intercellular communication and astrocyte heterogeneity. Brain Res 2012; 1487: 88-98
72. Eugenin EA, Basilio D, Sáez JC, Orellana JA, Raine CS, Bukauskas F, Bennett MVL, Berman JW. The role of gap junction channels during physiologic and pathologic conditions of the human central nervous system. J Neuroimmune Pharmacol 2012; 7: 499-518
73. Maragakis NJ, Rothstein JD. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006; 2: 679-689
74. Rose CR, Ransom BR. Regulation of intracellular sodium in cultured rat hippocampal neurones. J Physiol 1997; 499: 573-587
75. Wallraff A, Köhling R, Heinemann U, Theis M, Willecke K, Steinhäuser C. The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. J Neurosci 2006; 26: 5438-5447
76. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007; 10: 1369-1376
77. Tabernero A, Medina JM, Giaume C. Glucose metabolism and proliferation in glia: role of astrocytic gap junctions. J Neurochem 2006; 99: 1049-1061
78. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140: 918-934
79. Date I, Kawamura K, Nakashima H. Histological signs of immune reactions against allogeneic solid fetal neural grafts in the mouse cerebellum depend on the MHC locus. Exp Brain Res 1988; 73: 15-22
80. Lawrence JM, Morris RJ, Wilson DJ, Raisman G. Mechanisms of allograft rejection in the rat brain. Neuroscience 1990; 37: 431-462
81. Shinoda M, Hudson JL, Strömberg I, Hoffer BJ, Moorhead JW, Olson L. Microglial cell responses to fetal ventral mesencephalic tissue grafting and to active and adoptive immunizations. Exp Neurol 1996; 141: 173-180
82. Cicchetti F, Soulet D, Freeman TB. Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 2011; 134: 641-652
83. Garden GA, Möller T. Microglia biology in health and disease. J Neuroimmune Pharmacol 2006; 1: 127-137
84. Simard AR, Soulet D, Gowing G, Julien J-P, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49: 489-502
85. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318
86. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, Martel L, Levey AE, Mufson EJ, Freeman TB, Olanow CW. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996; 370: 203-230
87. Brundin P, Karlsson J, Emgård M, Schierle GS, Hansson O, Petersén A, Castilho RF. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 2000; 9: 179-195
88. Sortwell CE. Strategies for the augmentation of grafted dopamine neuron survival. Front Biosci 2003; 8: s522-532
89. Terpstra BT, Collier TJ, Marchionini DM, Levine ND, Paumier KL, Sortwell CE. Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons. J Neurosci Methods 2007; 166: 13-19
90. Cisbani G, Saint-Pierre M, Cicchetti F. Single cell suspension methodology favours survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington's disease. Cell Transplant 2013. doi: 10.3727/096368913X668636 [Epub ahead of print]
91. Mayer E, Fawcett JW, Dunnett SB. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons - II. Effects on nigral transplants in vivo. Neuroscience 1993; 56: 389-398
92. Apostolides C, Sanford E, Hong M, Mendez I. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 1998; 83: 363-372
93. Wang Y, Tien LT, Lapchak PA, Hoffer BJ. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats. Cell Tissue Res 1996; 286: 225-233
94. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, Weerasinghe S, King D, Desrosiers J, Darvesh S, Acorn T, Robertson H. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 2000; 92: 863-869
95. Zhou J, Bradford HF, Stern GM. Influence of BDNF on the expression of the dopaminergic phenotype of tissue used for brain transplants. Brain Res Dev Brain Res 1997; 100: 43-51
96. Du X, Iacovitti L. Synergy between growth factors and transmitters required for catecholamine differentiation in brain neurons. J Neurosci 1995; 15: 5420-5427
97. Du X, Stull ND, Iacovitti L. Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons. Brain Res 1995; 680: 229-233
98. Melo CV, Okumoto S, Gomes JR, Baptista MS, Bahr BA, Frommer WB, Duarte CB. Spatiotemporal resolution of BDNF neuroprotection against glutamate excitotoxicity in cultured hippocampal neurons. Neuroscience 2013; 237: 66-86
99. Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 2005; 20: 187-198
100. Bemelmans A-P, Husson I, Jaquet M, Mallet J, Kosofsky BE, Gressens P. Lentiviral-mediated gene transfer of brain-derived neurotrophic factor is neuroprotective in a mouse model of neonatal excitotoxic challenge. J Neurosci Res 2006; 83: 50-60
101. Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005; 25: 6251-6259
102. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856-860
103. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009; 5: 311-322
104. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007; 81: 294-330
105. Raju DV, Smith Y. Differential localization of vesicular glutamate transporters 1 and 2 in the rat striatum. The Basal Ganglia VIII 2005; 56: 601-610
106. Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, Bachoud-Lévi A-C, Tabrizi SJ, Di Donato S, Cattaneo E. Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS ONE 2011; 6: e22966
107. Ferrer I, Goutan E, Marín C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000; 866: 257-261
108. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008; 9: 741-745
109. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719
110. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penney D, Fink JS, Isacson O. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000; 54: 1042-1050
111. Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, Edge A, Penney D, Kassissieh S, Dempsey P, Isacson O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 1997; 3: 350-353
112. Lindsay RM, Raisman G. An autoradiographic study of neuronal development, vascularization and glial cell migration from hippocampal transplants labelled in intermediate explant culture. Neuroscience 1984; 12: 513-530
113. Geny C, Naimi-Sadaoui S, Jény R, Belkadi AM, Juliano SL, Peschanski M. Long-term delayed vascularization of human neural transplants to the rat brain. J Neurosci 1994; 14: 7553-7562
114. Broadwell RD, Charlton HM, Ebert PS, Hickey WF, Shirazi Y, Villegas J, Wolf AL. Allografts of CNS tissue possess a blood-brain barrier. II. Angiogenesis in solid tissue and cell suspension grafts. Exp Neurol 1991; 112: 1-28
115. Nikkhah G, Cunningham MG, Jödicke A, Knappe U, Björklund A. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res 1994; 633: 133-143
116. Scott DE. Fetal hypothalamic transplants: neuronal and neurovascular interrelationships. Neurosci Lett 1984; 51: 93-98
117. Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, Rafols JA. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 2000; 60: 55-69
118. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506
119. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503
120. Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012; 149: 968-977
121. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11: 301-307
122. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci USA 2009; 106: 12571-12572
123. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM-Y. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 2013; 154: 103-117
124. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez A, Fernagut PO, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E, Vila M. Lewy body extracts from Parkinson's disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2013. doi: 10.1002/ana.24066 [Epub ahead of print]
125. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012; 73: 685-697.
126. Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, Boncristiano S, Mathews PM, Mercken M, Abramowski D, Staufenbiel M, Jucker M. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 2003; 6: 370-377.
127. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009; 106: 13010-13015
128. Hansen C, Angot E, Bergström A-L, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li J-Y, Brundin P. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-725
129. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM-Y. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949-953
130. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM-Y. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012; 209: 975-986
131. Angot E, Steiner JA, Lema Tomé CM, Ekström P, Mattsson B, Björklund A, Brundin P. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE 2012; 7: e39465
132. Goedert M, Clavaguera F, Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33: 317-325
133. Herrera F, Tenreiro S, Miller-Fleming L, Outeiro TF. Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr 2011; 3: RRN1210
134. Costanzo M, Abounit S, Marzo L, Danckaert A, Chamoun Z, Roux P, Zurzolo C. Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J Cell Sci 2013; 126: 3678-3685
135. Ren P-H, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11: 219-225
136. Bradford J, Shin J-Y, Roberts M, Wang C-E, Sheng G, Li S, Li X-J. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 2010; 285: 10653-10661
137. Bradford J, Shin J-Y, Roberts M, Wang C-E, Li X-J, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009; 106: 22480-22485
138. Dunnett SB. Neural tissue transplantation, repair, and rehabilitation. Handb Clin Neurol 2013; 110: 43-59
139. Freeman TB, Cicchetti F, Bachoud-Lévi AC, Dunnett SB. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol 2011; 227: 1-9
140. Olsson M, Björklund A, Campbell K. Early specification of striatal projection neurons and interneuronal subtypes in the lateral and medial ganglionic eminence. Neuroscience 1998; 84: 867-876
141. Deacon TW, Pakzaban P, Isacson O. The lateral ganglionic eminence is the origin of cells committed to striatal phenotypes: neural transplantation and developmental evidence. Brain Res 1994; 668: 211-219
142. Olsson M, Nikkhah G, Bentlage C, Björklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995; 15: 3863-3875
143. Watts C, Brasted PJ, Dunnett SB. Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease. Exp Neurol 2000; 163: 85-97
144. TransEUro consortium. Available at: http://www.transeuro.org.uk/pages/objectives.html
145. Freeman TB, Brundin P. Important aspects of surgical methodology for transplantation in Parkinson's disease. Restorative Therapies in Parkinson's Disease. P Brundin, CW Olanow, 7th edn. Berlin: Springer, 2006
146. Emgård M, Blomgren K, Brundin P. Characterisation of cell damage and death in embryonic mesencephalic tissue: a study on ultrastructure, vital stains and protease activity. Neuroscience 2002; 115: 1177-1187
147. Watts C, Brasted PJ, Dunnett SB. The morphology, integration, and functional efficacy of striatal grafts differ between cell suspensions and tissue pieces. Cell Transplant 2000; 9: 395-407
148. Baker-Cairns BJ, Sloan DJ, Broadwell RD, Puklavec M, Charlton HM. Contributions of donor and host blood vessels in CNS allografts. Exp Neurol 1996; 142: 36-46
149. Krum JM, Rosenstein JM. Patterns of angiogenesis in neural transplant models: II. Fetal neocortical transplants. J Comp Neurol 1988; 271: 331-345
150. Broadwell RD, Charlton HM, Ebert P, Hickey WF, Villegas JC, Wolf AL. Angiogenesis and the blood-brain barrier in solid and dissociated cell grafts within the CNS. Prog Brain Res 1990; 82: 95-101
151. Rosenstein JM, Brightman MW. Alterations of the blood-brain barrier after transplantation of autonomic ganglia into the mammalian central nervous system. J Comp Neurol 1986; 250: 339-351
152. Brundin P, Nilsson OG, Gage FH, Björklund A. Cyclosporin A increases survival of cross-species intrastriatal grafts of embryonic dopamine-containing neurons. Exp Brain Res 1985; 60: 204-208
153. Brundin P, Strecker RE, Widner H, Clarke DJ, Nilsson OG, Astedt B, Lindvall O, Björklund A. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 1988; 70: 192-208
154. Brundin P, Widner H, Nilsson OG, Strecker RE, Björklund A. Intracerebral xenografts of dopamine neurons: the role of immunosuppression and the blood-brain barrier. Exp Brain Res 1989; 75: 195-207
155. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-414
156. Kordower JH, Styren S, Clarke M, DeKosky ST, Olanow CW, Freeman TB. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 1997; 6: 213-219
157. Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2: 1137-1140
158. Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brooks D, Brundin P, Frackowiak R, Marsden CD, Odin P. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-180
159. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999; 56: 179-187
160. Barker RA, Widner H. Immune problems in central nervous system cell therapy. NeuroRx 2004; 1: 472-481
161. Mendez I, Sanchez-Pernaute R, Cooper O, Viñuela A, Ferrari D, Björklund L, Dagher A, Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005; 128: 1498-1510
162. Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008; 14: 507-509
163. Redmond DE, Vinuela A, Kordower JH, Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis 2008; 29: 103-116
164. Sokal RR, Rohlf FJ. Biometry. 3rd edn. New York: Macmillan, 1995